91 related articles for article (PubMed ID: 16019529)
21. Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
Caimi PF; William BM; Silva Rondon CH; Fu P; Cooper BW; Campagnaro EL; Gerson SL; Reese-Koc J; Fox R; Creger RJ; de Lima M; Lazarus HM
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1926-31. PubMed ID: 26087475
[TBL] [Abstract][Full Text] [Related]
22. Clearing minimal residual disease with rituximab consolidation therapy.
Brugger W
Semin Oncol; 2004 Feb; 31(1 Suppl 2):33-7. PubMed ID: 15042533
[TBL] [Abstract][Full Text] [Related]
23. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma.
Tam CS; Bassett R; Ledesma C; Korbling M; Alousi A; Hosing C; Kebraei P; Harrell R; Rondon G; Giralt SA; Anderlini P; Popat U; Pro B; Samuels B; Hagemeister F; Medeiros LJ; Champlin RE; Khouri IF
Blood; 2009 Apr; 113(18):4144-52. PubMed ID: 19168784
[TBL] [Abstract][Full Text] [Related]
24. Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response.
Foran JM; Cunningham D; Coiffier B; Solal-Celigny P; Reyes F; Ghielmini M; Johnson PW; Gisselbrecht C; Bradburn M; Matthews J; Lister TA
Ann Oncol; 2000; 11 Suppl 1():117-21. PubMed ID: 10707792
[TBL] [Abstract][Full Text] [Related]
25. Iodine-131 rituximab radioimmunotherapy with BEAM conditioning and autologous stem cell transplant salvage therapy for relapsed/refractory aggressive non-Hodgkin lymphoma.
Kruger PC; Cooney JP; Turner JH
Cancer Biother Radiopharm; 2012 Nov; 27(9):552-60. PubMed ID: 23062193
[TBL] [Abstract][Full Text] [Related]
26. In vivo purging with rituximab prior to collection of stem cells for autologous transplantation in chronic lymphocytic leukemia.
Berkahn L; Simpson D; Raptis A; Klingemann HG
J Hematother Stem Cell Res; 2002 Apr; 11(2):315-20. PubMed ID: 11983102
[TBL] [Abstract][Full Text] [Related]
27. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients.
Milpied N; Vasseur B; Parquet N; Garnier JL; Antoine C; Quartier P; Carret AS; Bouscary D; Faye A; Bourbigot B; Reguerre Y; Stoppa AM; Bourquard P; Hurault de Ligny B; Dubief F; Mathieu-Boue A; Leblond V
Ann Oncol; 2000; 11 Suppl 1():113-6. PubMed ID: 10707791
[TBL] [Abstract][Full Text] [Related]
28. Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma.
Kasamon YL; Jones RJ; Brodsky RA; Fuchs EJ; Matsui W; Luznik L; Powell JD; Blackford AL; Goodrich A; Gocke CD; Abrams RA; Ambinder RF; Flinn IW
Ann Oncol; 2010 Jun; 21(6):1203-1210. PubMed ID: 19880437
[TBL] [Abstract][Full Text] [Related]
29. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
30. Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue.
Hohloch K; Sahlmann CO; Lakhani VJ; Wulf G; Glass B; Hasenkamp J; Meller J; Riggert J; Trümper L; Griesinger F
Ann Hematol; 2011 Nov; 90(11):1307-15. PubMed ID: 21360108
[TBL] [Abstract][Full Text] [Related]
31. High rate and prolonged duration of complete remissions induced by rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide, cytarabine, and thalidomide (R-MACLO-IVAM-T), a modification of the National Cancer Institute 89-C-41 regimen, in patients with newly diagnosed mantle cell lymphoma.
Lossos IS; Hosein PJ; Morgensztern D; Coleman F; Escalón MP; Byrne GE; Rosenblatt JD; Walker GR
Leuk Lymphoma; 2010 Mar; 51(3):406-14. PubMed ID: 20038221
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as 'in vivo purge' and consolidative immunotherapy following autologous stem cell transplantation.
Mangel J; Buckstein R; Imrie K; Spaner D; Franssen E; Pavlin P; Boudreau A; Pennell N; Combs D; Berinstein NL
Ann Oncol; 2003 May; 14(5):758-65. PubMed ID: 12702531
[TBL] [Abstract][Full Text] [Related]
33. Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.
Ladetto M; Magni M; Pagliano G; De Marco F; Drandi D; Ricca I; Astolfi M; Matteucci P; Guidetti A; Mantoan B; Bodoni CL; Zanni M; Boccadoro M; Gianni AM; Tarella C
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1270-6. PubMed ID: 17162208
[TBL] [Abstract][Full Text] [Related]
34. Ofatumumab Exhibits Enhanced In Vitro and In Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma.
Barth MJ; Mavis C; Czuczman MS; Hernandez-Ilizaliturri FJ
Clin Cancer Res; 2015 Oct; 21(19):4391-7. PubMed ID: 25964296
[TBL] [Abstract][Full Text] [Related]
35. Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?
Epperla N; Fenske TS; Lazarus HM; Hamadani M
Bone Marrow Transplant; 2015 Nov; 50(11):1393-404. PubMed ID: 26281033
[TBL] [Abstract][Full Text] [Related]
36. Mantle cell lymphoma: new treatments targeted to the biology.
Bertoni F; Ghielmini M; Cavalli F; Cotter FE; Zucca E
Clin Lymphoma; 2002 Sep; 3(2):90-6. PubMed ID: 12435282
[TBL] [Abstract][Full Text] [Related]
37. Favorable consolidative effect of high-dose melphalan and total-body irradiation followed by autologous peripheral blood stem cell transplantation after rituximab-containing induction chemotherapy with in vivo purging in relapsed or refractory follicular lymphoma.
Kato H; Taji H; Ogura M; Kagami Y; Oki Y; Tsujimura A; Fuwa N; Kodaira T; Seto M; Yamamoto K; Morishima Y
Clin Lymphoma Myeloma; 2009 Dec; 9(6):443-8. PubMed ID: 19951884
[TBL] [Abstract][Full Text] [Related]
38. 131I-Anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital.
Turner JH; Martindale AA; Boucek J; Claringbold PG; Leahy MF
Cancer Biother Radiopharm; 2003 Aug; 18(4):513-24. PubMed ID: 14503945
[TBL] [Abstract][Full Text] [Related]
39. Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma.
Jiang VC; Liu Y; Jordan A; Leeming A; McIntosh J; Huang S; Zhang R; Cai Q; Chen Z; Li Y; Che Y; Nie L; Karlsson I; Mårtensson L; Kovacek M; Teige I; Frendéus B; Wang M
J Hematol Oncol; 2022 Apr; 15(1):42. PubMed ID: 35410313
[TBL] [Abstract][Full Text] [Related]
40. A prospective phase II study of RICE re-induction, then high-dose fludarabine and busulfan, followed by autologous or allogeneic blood stem cell transplantation for indolent b-cell lymphoma.
Stewart DA; Duan Q; Carlson L; Russell JA; Bahlis NJ; Duggan P; Hasegawa W; Voralia M
Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):475-82. PubMed ID: 21831743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
